Source:http://linkedlifedata.com/resource/pubmed/id/11438819
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
2001-7-4
|
| pubmed:abstractText |
A hundred and eight patients less than 60 years old with de novo acute myeloid leukemia were treated between 1982 and 1994 by protocols including final intensification with a transplant using autologous bone marrow purged by mafosfamide in first remission in the absence of an HLA-matched sibling donor available for allograft. From 1989, we attempted to improve tumor control by using high-dose anthracyclines in induction, by increasing from one to two the number of consolidation courses pre-transplant and by introducing intermediate doses of cytarabine in the first consolidation course. The CR rate was 77% (33/43) before 1989 and 90% (59/65) after 1989 (P = 0.06). Forty-five out of the 59 patients (76%) who achieved CR after 1989 could undergo bone marrow grafting in CR1 vs 16/33 (48%) before 1989 (P = 0.01). In spite of the higher proportion of patients above 50 years after 1989 (32%) toxicity was mild and an adequate graft was obtained more frequently after one collection. The principal factor relating to improvement in graft feasibility was the post-1989 modification of induction and consolidation regimens. This improvement in graft feasibility was associated with a better disease-free survival (DFS) (48 +/- 7% vs 32 +/- 8%, P = 0.04) and overall survival (OS) (53 +/- 6% vs 30 +/- 7%, P = 0.007) at 5 years. By multivariate analysis four factors were associated with overall survival (OS): karyotype, white blood cell count at diagnosis, treatment regimen and bone marrow grafting in CR1. This global approach should be prospectively compared with intensive chemotherapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0268-3369
|
| pubmed:author |
pubmed-author:AoudjhaneMM,
pubmed-author:ChérotPP,
pubmed-author:DelouxJJ,
pubmed-author:DouayLL,
pubmed-author:ElloumiMM,
pubmed-author:FouillardLL,
pubmed-author:GorinN CNC,
pubmed-author:GuiguetMM,
pubmed-author:IsnardFF,
pubmed-author:LaporteJ PJP,
pubmed-author:LesageSS,
pubmed-author:LopezMM,
pubmed-author:NajmanAA,
pubmed-author:Van Den AkkerJJ,
pubmed-author:ZuninEE
|
| pubmed:issnType |
Print
|
| pubmed:volume |
27
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1045-52
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:11438819-Acute Disease,
pubmed-meshheading:11438819-Adolescent,
pubmed-meshheading:11438819-Adult,
pubmed-meshheading:11438819-Amsacrine,
pubmed-meshheading:11438819-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11438819-Bone Marrow Transplantation,
pubmed-meshheading:11438819-Cytarabine,
pubmed-meshheading:11438819-Etoposide,
pubmed-meshheading:11438819-Female,
pubmed-meshheading:11438819-Humans,
pubmed-meshheading:11438819-Leukemia, Myeloid,
pubmed-meshheading:11438819-Male,
pubmed-meshheading:11438819-Middle Aged,
pubmed-meshheading:11438819-Remission Induction,
pubmed-meshheading:11438819-Retrospective Studies,
pubmed-meshheading:11438819-Survival Rate,
pubmed-meshheading:11438819-Transplantation, Autologous,
pubmed-meshheading:11438819-Treatment Outcome
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution.
|
| pubmed:affiliation |
Service des Maladies du Sang, Hòpital Saint Antoine, Paris, France.
|
| pubmed:publicationType |
Journal Article
|